• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Top 10 sessions to attend at AMCP Nexus 2015

Article

Traveling to Orlando for AMCP Nexus 2015? Make the most out of your trip by attending these presentations. View the top 10.

 

This year’s Academy of Managed Care Pharmacy (AMCP) Nexus 2015, held in Orlando, will feature a wide array of sessions. To help you create a smart itinerary, Managed Healthcare Executive has identified 10 must-attend sessions.

View our Events Calendar to plan ahead for more upcoming events.

 

 

During this session, presenter Aimee Theraldson, PharmD, senior clinical consultant, emerging therapeutics, at Express Scripts, will identify new and emerging specialty medications. She will share how these medications will affect the healthcare landscape and the managed care market.

 

This session will provide updates on the latest federal and state legislative and regulatory actions affecting managed care. Topics will include: the Affordable Care Act, Medicare Part D changes, and limits on specialty tiers. Presenters include: Regina Grayson Benjamin, JD, director of legislative affairs, ACMP; and Mary Jo Carden, RPh, JD, vice president, government and pharmacy affairs, ACMP.

 

 

 

 

 

This session will be presented by Kristina Lunner, senior director, Leavitt Partners and Jeff Rochon, PharmD, chief executive officer, Washington State Pharmacy Association. This session will provide an overview and update of pharmacist provider status activities at the federal and state level. It will also identify one state that is leading the way in this effort, including how that state is working with payers to reimburse pharmacists as providers.

 

 

Presented by:
Jody H. Allen, BS, PharmD, FASHP
Dan Danielson, MS, RPh
John Watkins, PharmD, MPH, BCPS

This session will be presented by Jody H. Allen, vice president, clinical account management, Express Scripts; Dan Danielson, pharmacy manager, clinical services, Premera Blue Cross; and John Watkins, pharmacy manager, formulary development, Premera Blue Cross. Presenters will discuss emerging cholesterol treatments and provide a clinical and economic evaluation.

 

 

 

Wednesday, October 28

8:15 a.m. to 9:45 a.m.

Presented by:
Amy M. Lugo, PharmD, BCPS
Healther Sundar, PharmD

This session will explore how payers can improve the diabetes health management. It will discuss evidence for recent pharmaceutical agents, biosimilar opportunities for insulin products, and quality improvement directions that can be employed by payers. Presenters include Amy M. Lugo, PharmD, clinical pharmacy specialist at the Defense Health Agency Pharmacy Operations Division; and Heather Sundar, PharmD, vice president, clinical, research, and new solutions at Express Scripts.

 

 

Wednesday, October 28

10:05 a.m. to 11:35 a.m.

FDA approved the first biosimilar in March. This session will provide an overview of the regulatory landscape for biosimilars and it will explore the implications of the U.S. being part of the biosimilar marketplace. This session will be presented by Kevin M. Nelson, JD, partner, Duane Morris, LLP and Gillian Woollett, MA, FDA practice head, senior vice president, Avalere.

 

 

Wednesday, October 28

2:30 p.m. to 4:00 p.m.

This session will discuss medication therapy management (MTM) and how a patient-centric, coordinated approach to MTM can address accountable care and shared risk. It will also explore the future of population health driven MTM services. The session will be presented by Travis J. Gau, PharmD, clinical account manager, Medication Management Systems, Inc., and Jennifer Strohecker Hellinga, PharmD, BCPS, director Medicare pharmacy, clinical operations, Molina Healthcare.

 

Wednesday, October 28

4:20 p.m. to 5:50 p.m.

This interactive session will feature Elizabeth Carpenter and Josh Seidman, of Avalere. They will look at how key trends could shape how payers and patients will approach insurance in the U.S. in the future.

 

Thursday, October 29

This session will explore how oncology pathways have led to cost-effective care, and discuss future challenges and solutions for incorporating more complex therapeutic agents into pathways. The session will be presented by Andrew Hertler, MD, FACP, chief medical officer, New Century Health; and Edward Li, PharmD, MPH, BCOP, associate professor of pharmacy practice, University of New England College of Pharmacy.

 

Thursday, October 29

This session, presented by Jim Carlson, vice president, professional pharmacy services, OmedaRx and Matt Cheung, consultant and owner of Advanced Rx Consulting, LLC, will provide an overview of some of the most common rare disease states and orphan drugs which can help treat them and best practices on orphan drug management.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.